PCSA
Processa Pharmaceuticals, Inc.$2.90-0.09 (-2.85%)Prev Close$2.98·MCap$6.3M·P/E—·Vol3.3K·Yield—
▲
Buys (12M)
14
$71.1K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$71.1K
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Processa Pharmaceuticals, Inc. (PCSA) has been exclusively buying, with 14 insider purchases totaling $71.1K and 0 insider sales totaling $0.00. The most recent insider transaction was by SKIBSTED RUSSELL (officer: Chief Financial Officer), who purchased $5.9K worth of shares on Apr 17, 2026. Processa Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $6.3M.
PCSA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 1,984 | $2.97 | $5.9K | 4,308+85% |
| Apr 17, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,799 | $2.97 | $5.3K | 5,510+48% |
| Apr 17, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,583 | $2.97 | $4.7K | 4,693+51% |
| Apr 17, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 1,843 | $2.97 | $5.5K | 5,492+51% |
| Apr 17, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,545 | $2.97 | $4.6K | 12,107 |
| Apr 17, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4.1K | 4,725+41% |
| Apr 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,810 | $2.54 | $4.6K | 10,562 |
| Apr 1, 2026 | Baluch Khoso | director | Buy | 2,269 | $2.53 | $5.8K | 2,325New Position |
| Apr 1, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 2,107 | $2.53 | $5.3K | 3,711+131% |
| Apr 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,854 | $2.54 | $4.7K | 3,110+148% |
| Apr 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,603 | $2.54 | $4.1K | 3,356+91% |
| Apr 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,324 | $2.53 | $5.9K | 2,324 |
| Apr 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,136 | $2.53 | $5.4K | 3,649+141% |
| Apr 1, 2026 | Pannu Geraldine | director | Buy | 2,072 | $2.54 | $5.3K | 2,188New Position |
| Apr 1, 2025 | Young David | Pres. Research & Development | Sell | 5,345 | $0.41 | $2.2K | 0 |
| Jan 31, 2025 | Yorke Justin W | Buy | 12,400 | $0.80 | $9.9K0.5% OS | 12,400 | |
| Jan 29, 2025 | Lin Patrick | Chief Business - Strategy Off | Buy | 43,500 | $0.80 | $34.7K1.9% OS | 43,500 |
| Jan 29, 2025 | Ng George K | Chief Executive Officer | Buy | 87,200 | $0.80 | $69.5K3.8% OS | 87,200 |
| Jan 29, 2025 | Young David | Pres. Research & Development | Buy | 124,500 | $0.80 | $99.3K5.5% OS | 205,405+154% |
| Feb 8, 2024 | Young David | Pres. Research & Development | Buy | 21,000 | $2.45 | $51.5K0.9% OS | 79,387+36% |
| Feb 7, 2024 | Young David | Pres. Research & Development | Buy | 20,000 | $2.53 | $50.5K0.9% OS | 58,387+52% |
| Feb 1, 2024 | Lin Patrick | Chief Business - Strategy Off | Buy | 4,000 | $2.38 | $9.5K | 27,478 |
| Jan 31, 2024 | Ng George K | Chief Executive Officer | Buy | 10,000 | $2.70 | $27.0K | 20,000+100% |
| Jan 31, 2024 | Yorke Justin W | Buy | 8,000 | $2.69 | $21.5K | 31,232+34% | |
| Jun 12, 2023 | Young David | President & CEO | Buy | 40,000 | $0.80 | $32.0K1.8% OS | 470,424 |
| Apr 14, 2023 | Young David | President & CEO | Buy | 20,000 | $0.55 | $11.0K0.9% OS | 430,424 |
| Apr 13, 2023 | Young David | President & CEO | Buy | 60,000 | $0.48 | $29.0K2.6% OS | 410,424 |
| May 19, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $1.59 | $3.2K | 433,390 |
| Apr 8, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $3.29 | $6.6K | 431,390 |
| Jan 31, 2022 | Yorke Justin W | Director | Sell | 1,854 | $3.30 | $6.1K | 532,563 |
| Jan 4, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,000 | $4.00 | $12.0K | 429,390 |
| Dec 7, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,500 | $4.80 | $16.8K | 426,390 |
| Dec 7, 2021 | Yorke Justin W | Director | Sell | 9,700 | $4.78 | $46.4K | 538,617 |
| Aug 30, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 4,000 | $6.02 | $24.1K | 422,890 |
| Jun 23, 2021 | Young David | Chief Executive Officer | Buy | 10,000 | $7.67 | $76.7K | 345,190 |
| Jun 22, 2021 | Floyd Robert Michael | Chief Operating Officer | Buy | 2,000 | $7.03 | $14.1K | 28,000 |
| Jun 22, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $6.65 | $13.3K | 401,737 |
| Jun 22, 2021 | Stanker James H | Chief Financial Officer | Buy | 1,000 | $6.81 | $6.8K | 36,510 |
| Apr 15, 2021 | Yorke Justin W | Director | Sell | 16,200 | $9.60 | $155.5K0.7% OS | 257,972 |
| Apr 8, 2021 | BESSER JAMES E | Sell | 447,771 | $10.77 | $4.82M19.8% OS | 1,064,300-30% |
PCSA Insider Buying Activity
The following table shows recent insider purchases of Processa Pharmaceuticals, Inc. (PCSA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 1,984 | $2.97 | $5.9K | 4,308+85% |
| Apr 17, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 1,799 | $2.97 | $5.3K | 5,510+48% |
| Apr 17, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,583 | $2.97 | $4.7K | 4,693+51% |
| Apr 17, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 1,843 | $2.97 | $5.5K | 5,492+51% |
| Apr 17, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,545 | $2.97 | $4.6K | 12,107 |
| Apr 17, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,369 | $2.97 | $4.1K | 4,725+41% |
| Apr 1, 2026 | Young David | director, officer: Pres. Research & Development | Buy | 1,810 | $2.54 | $4.6K | 10,562 |
| Apr 1, 2026 | Baluch Khoso | director | Buy | 2,269 | $2.53 | $5.8K | 2,325New Position |
| Apr 1, 2026 | Bigora Sian | officer: Chief Development Officer | Buy | 2,107 | $2.53 | $5.3K | 3,711+131% |
| Apr 1, 2026 | Guy Wendy | officer: Chief Administrative Officer | Buy | 1,854 | $2.54 | $4.7K | 3,110+148% |
| Apr 1, 2026 | Lin Patrick | officer: Chief Business - Strategy Off | Buy | 1,603 | $2.54 | $4.1K | 3,356+91% |
| Apr 1, 2026 | SKIBSTED RUSSELL | officer: Chief Financial Officer | Buy | 2,324 | $2.53 | $5.9K | 2,324 |
| Apr 1, 2026 | Ng George K | director, officer: Chief Executive Officer | Buy | 2,136 | $2.53 | $5.4K | 3,649+141% |
| Apr 1, 2026 | Pannu Geraldine | director | Buy | 2,072 | $2.54 | $5.3K | 2,188New Position |
| Jan 31, 2025 | Yorke Justin W | Buy | 12,400 | $0.80 | $9.9K0.5% OS | 12,400 | |
| Jan 29, 2025 | Lin Patrick | Chief Business - Strategy Off | Buy | 43,500 | $0.80 | $34.7K1.9% OS | 43,500 |
| Jan 29, 2025 | Ng George K | Chief Executive Officer | Buy | 87,200 | $0.80 | $69.5K3.8% OS | 87,200 |
| Jan 29, 2025 | Young David | Pres. Research & Development | Buy | 124,500 | $0.80 | $99.3K5.5% OS | 205,405+154% |
| Feb 8, 2024 | Young David | Pres. Research & Development | Buy | 21,000 | $2.45 | $51.5K0.9% OS | 79,387+36% |
| Feb 7, 2024 | Young David | Pres. Research & Development | Buy | 20,000 | $2.53 | $50.5K0.9% OS | 58,387+52% |
| Feb 1, 2024 | Lin Patrick | Chief Business - Strategy Off | Buy | 4,000 | $2.38 | $9.5K | 27,478 |
| Jan 31, 2024 | Ng George K | Chief Executive Officer | Buy | 10,000 | $2.70 | $27.0K | 20,000+100% |
| Jan 31, 2024 | Yorke Justin W | Buy | 8,000 | $2.69 | $21.5K | 31,232+34% | |
| Jun 12, 2023 | Young David | President & CEO | Buy | 40,000 | $0.80 | $32.0K1.8% OS | 470,424 |
| Apr 14, 2023 | Young David | President & CEO | Buy | 20,000 | $0.55 | $11.0K0.9% OS | 430,424 |
| Apr 13, 2023 | Young David | President & CEO | Buy | 60,000 | $0.48 | $29.0K2.6% OS | 410,424 |
| May 19, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $1.59 | $3.2K | 433,390 |
| Apr 8, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $3.29 | $6.6K | 431,390 |
| Jan 4, 2022 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,000 | $4.00 | $12.0K | 429,390 |
| Dec 7, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 3,500 | $4.80 | $16.8K | 426,390 |
| Aug 30, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 4,000 | $6.02 | $24.1K | 422,890 |
| Jun 23, 2021 | Young David | Chief Executive Officer | Buy | 10,000 | $7.67 | $76.7K | 345,190 |
| Jun 22, 2021 | Floyd Robert Michael | Chief Operating Officer | Buy | 2,000 | $7.03 | $14.1K | 28,000 |
| Jun 22, 2021 | Lin Patrick | Chief Business - Strategy Off | Buy | 2,000 | $6.65 | $13.3K | 401,737 |
| Jun 22, 2021 | Stanker James H | Chief Financial Officer | Buy | 1,000 | $6.81 | $6.8K | 36,510 |
PCSA Insider Selling Activity
The following table shows recent insider sales of Processa Pharmaceuticals, Inc. (PCSA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | Young David | Pres. Research & Development | Sell | 5,345 | $0.41 | $2.2K | 0 |
| Jan 31, 2022 | Yorke Justin W | Director | Sell | 1,854 | $3.30 | $6.1K | 532,563 |
| Dec 7, 2021 | Yorke Justin W | Director | Sell | 9,700 | $4.78 | $46.4K | 538,617 |
| Apr 15, 2021 | Yorke Justin W | Director | Sell | 16,200 | $9.60 | $155.5K0.7% OS | 257,972 |
| Apr 8, 2021 | BESSER JAMES E | Sell | 447,771 | $10.77 | $4.82M19.8% OS | 1,064,300-30% |
PCSA Insiders
Similar Stocks to PCSA
VRTX
Vertex Pharmaceuticals Incorporated
$429.19+0.77%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$740.38-0.55%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$305.79-0.88%
$41.24B
INSM
Insmed Incorporated
$133.47-1.85%
$30.79B
RVMD
Revolution Medicines, Inc.
$146.58+11.18%
$29.51B
UTHR
United Therapeutics Corporation
$566.52-0.06%
$25.13B
MRNA
Moderna, Inc.
$46.88-3.78%
$21.42B
RPRX
Royalty Pharma plc
$49.86+0.42%
$21.20B